TW200716114A - Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof - Google Patents

Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof

Info

Publication number
TW200716114A
TW200716114A TW095120061A TW95120061A TW200716114A TW 200716114 A TW200716114 A TW 200716114A TW 095120061 A TW095120061 A TW 095120061A TW 95120061 A TW95120061 A TW 95120061A TW 200716114 A TW200716114 A TW 200716114A
Authority
TW
Taiwan
Prior art keywords
phthalazin
micronised
pyridylmethyl
chlorophenyl
immediate
Prior art date
Application number
TW095120061A
Other languages
English (en)
Inventor
Kai Juergens
Thomas Backensfeld
Thorsten Wagner
Adrian Funke
Kai Thode
Heiko Kranz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of TW200716114A publication Critical patent/TW200716114A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095120061A 2005-06-07 2006-06-06 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof TW200716114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090167A EP1731154A1 (en) 2005-06-07 2005-06-07 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof

Publications (1)

Publication Number Publication Date
TW200716114A true TW200716114A (en) 2007-05-01

Family

ID=34938468

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095120061A TW200716114A (en) 2005-06-07 2006-06-06 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof

Country Status (22)

Country Link
EP (2) EP1731154A1 (zh)
JP (1) JP2008542421A (zh)
KR (1) KR20080017443A (zh)
CN (1) CN101242841A (zh)
AR (1) AR054377A1 (zh)
AU (1) AU2006256853A1 (zh)
BR (1) BRPI0611818A2 (zh)
CA (1) CA2610977A1 (zh)
CR (1) CR9577A (zh)
CU (1) CU20070272A7 (zh)
DO (1) DOP2006000128A (zh)
EC (1) ECSP078037A (zh)
GT (1) GT200600243A (zh)
IL (1) IL187906A0 (zh)
MX (1) MX2007015495A (zh)
NO (1) NO20080066L (zh)
PE (1) PE20070012A1 (zh)
RU (1) RU2007147953A (zh)
TW (1) TW200716114A (zh)
UY (1) UY29585A1 (zh)
WO (1) WO2006131394A1 (zh)
ZA (1) ZA200800113B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958616A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
AR054377A1 (es) 2007-06-20
KR20080017443A (ko) 2008-02-26
CR9577A (es) 2008-03-06
PE20070012A1 (es) 2007-02-07
NO20080066L (no) 2008-03-06
RU2007147953A (ru) 2009-07-20
AU2006256853A1 (en) 2006-12-14
CA2610977A1 (en) 2006-12-14
BRPI0611818A2 (pt) 2010-09-28
ZA200800113B (en) 2009-07-29
ECSP078037A (es) 2008-01-23
EP1888073A1 (en) 2008-02-20
IL187906A0 (en) 2008-03-20
EP1731154A1 (en) 2006-12-13
DOP2006000128A (es) 2006-12-15
CU20070272A7 (es) 2010-09-30
WO2006131394A1 (en) 2006-12-14
JP2008542421A (ja) 2008-11-27
CN101242841A (zh) 2008-08-13
MX2007015495A (es) 2008-02-22
GT200600243A (es) 2007-07-16
UY29585A1 (es) 2007-01-31

Similar Documents

Publication Publication Date Title
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
MY161078A (en) Topical formulation for a jak inhibitor
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MX2009007784A (es) Composiciones de tiacumicinas estables.
WO2007014124A3 (en) High drug load formulations and dosage forms
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
TW200744583A (en) Statin stabilizing dosage formulations
WO2008004100A3 (en) Therapeutic compounds
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
UA106361C2 (ru) Фармацевтическая композиция для лечения эссенциальной тромбоцитемии